Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.54 |
| ▸ | LCK | P06239 | 3/20 | 0.52 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524749 | 0.85 | MAPK14 (0.68) | MAPK14LCKCSF1RMAP2K1KMT2A | |
| SCHEMBL3522459 | 0.84 | MAPK14 (0.56) | MAPK14LCKCSF1RMAP2K1KCNK3 | |
| SCHEMBL5124496 | 0.79 | MAPK14 (0.57) | MAPK14LCKCSF1RKMT2AKCNK3 | |
| SCHEMBL3529871 | 0.76 | MAPK14 (0.87) | MAPK14LCKCSF1RMAP2K1RAF1 | |
| SCHEMBL5113564 | 0.76 | MAPK14 (0.61) | MAPK14LCKCSF1RMAP2K1KMT2A | |
| SCHEMBL5110981 | 0.75 | HTR1D (0.54) | MAPK14LCKCSF1RKMT2ARAB9A | |
| SCHEMBL3522988 | 0.75 | MAPK14 (0.57) | MAPK14KMT2ANPC1RAB9AMAPK13 | |
| SCHEMBL4820863 | 0.73 | MAPK14 (0.74) | MAPK14KMT2AKCNK3KCNK9NPC1 | |
| SCHEMBL10227043 | 0.72 | KMT2A (0.67) | MAPK14KMT2AKCNK3KCNK9NPC1 | |
| SCHEMBL13546252 | 0.72 | MAPK14 (0.76) | MAPK14LCKCSF1RMAP2K1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | claimed |
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1531812-B1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1531812-B1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | MAPK7, CNKSR1, MAPK1 | MAPK14 11/4885LCK 303/4885CSF1R 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.